The molecular therapeutic targeting paradigm and the concept of synthetic lethality as exemplified by BRCA1/2 mutations and PARP inhibition offer profound opportunities for ovarian cancer drug development and discovery. The gene discussed is BRCA1; the disease is ovarian cancer.